Haisco(SZ:002653) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-09-02 01:11Group 1 - The core announcement is that HSK47977, an innovative drug developed by the company, has received FDA approval for clinical trials, indicating progress in its development [1][2]. - HSK47977 is an oral BCL6 PROTAC small molecule formulation aimed at targeting and degrading the BCL6 protein to inhibit tumor cell development, specifically for lymphoma treatment [1]. - The drug has shown strong anti-tumor activity and selectivity in preclinical studies, and it is positioned as a potential First-In-Class product, with no similar drugs in clinical stages in the domestic market [1]. Group 2 - The company also received a clinical trial approval notice from the National Medical Products Administration on August 11, 2025, and completed the enrollment of the first subject on August 28, 2025 [2].